Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Mar 3;8:219. doi: 10.3389/fimmu.2017.00219

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Alvarez Salazar, Cortés-Hernández, Alemán-Muench, Alberú, Rodríguez-Aguilera, Recillas-Targa, Chagoya de Sánchez, Cuevas, Mancilla-Urrea, Pérez García, Mondragón-Ramírez, Vilatobá, Bostock, Hernández-Méndez, De Rungs, García-Zepeda and Soldevila.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Reduced FOXP3 expression on BLT regulatory T cells (Tregs) is not a consequence of the accumulation of Tregs with naïve phenotype. Patients under BLT treatment showed an increase frequency of naïve Tregs (A); however, a reduced expression of FOXP3 (B) was found in both naïve (CD45RA⁺) and activated (CD45RA⁻) Tregs from patients under BLT (n = 14) treatment compared to CsA (n = 4) and controls (n = 9). (C) CD25 expression was significantly reduced in activated but not naïve Tregs from BLT patients. Statistical analysis was performed using non-parametric Mann–Whitney test, two tailed. BLT, belatacept; CsA, Cyclosporine A. Control group was composed by healthy individuals.